Allergy Therapeutics (AGY)

 

LSE:AGY: Issue of Equity

Allergy Therapeutics

13 Apr 2017 07:00:06

Allergy Therapeutics

RNS Number : 3752C
Allergy Therapeutics PLC
13 April 2017
 



 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Issue of equity in respect of the exercise of warrants and options

 

13 April 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces the issue and allotment of a total number of 673,748 new ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") pursuant to the exercise of 353,748 share warrants issued to JSB Partners, LP in 2012 and pursuant to the exercise of 320,000 share options by certain employees.

 

Application has been made to the London Stock Exchange for admission to trading of the new Ordinary Shares on AIM ("Admission"). It is expected that Admission will take place and that dealings in the new Ordinary Shares on AIM will commence at 8.00 a.m. on 18 April 2017. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new Ordinary Shares.

 

Allergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 594,117,768 Ordinary Shares with voting rights attached. The Company has no Ordinary Shares in Treasury; therefore the total number of voting rights in Allergy Therapeutics is 594,117,768. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan

[email protected]

 

Note to editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Group sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Group employs c.495 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEELLFFDZFZBBF